

SIGYN THERAPEUTICS, INC.

Poised to Emerge as the Top Blood Purification Segment Performer

Rob Goldman
rob@goldmanresearch.com

July 7, 2021

SIGYN THERAPEUTICS, INC. (OTC – SIGY - \$1.10)

Industry: Medical Devices

6-12 Mo. Price Target: \$9.00

COMPANY SNAPSHOT

Sigyn Therapeutics™ is a development-stage therapeutic technology company targeting a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Cytokine storm syndrome is the hallmark of sepsis, the most common cause of in-hospital deaths. Virus induced cytokine storm is a leading cause of COVID-19 deaths. Other therapeutic opportunities include bacteria induced cytokine storm, acute respiratory distress syndrome and acute forms of liver failure, such as hepatic encephalopathy.

KEY STATISTICS

Price as of 7/6/21	\$1.10
52 Week High – Low	\$3.50 - \$1.00
Est. Shares Outstanding	36.6M
Market Capitalization	\$40.3M
Average Volume	1,952
Exchange	OTCPK

COMPANY INFORMATION

Sigyn Therapeutics, Inc.
 8880 Rio San Diego Drive
 Suite 800
 San Diego, CA 92108

Web: www.SignTherapeutics.com
 Email: info@sigyntherapeutics.com
 Phone : 619-368-2000

INVESTMENT HIGHLIGHTS

Conclusion: SIGY peers have recently enjoyed major stock price gains and we believe that SIGY is next. Looking ahead, SIGY appears set to emerge as the top performing blood purification company in terms of leadership and wide-ranging capabilities, as well as intermediate term share price appreciation.

The Space: The blood purification therapeutic segment is in the early innings of garnering the attention of leading clinicians and physicians. Given the approach's wide-reaching therapeutic capabilities, the power of PR is just now placing a spotlight on the space. Why? Blood purification therapies are now demonstrating the unique capability to deliver life-saving mechanisms that are beyond the reach of post-infection drugs--especially during global health pandemics such as COVID-19.

SIGY Checks Boxes its Peers Cannot: The Sigyn Therapy™ under development is designed to treat life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (CSS), such as sepsis, COVID-19, etc. Unlike its peers, it appears that SIGY can address the source of high mortality inflammation induced by both viral pathogens bacterial toxins. Thus, the device may be the only one able to remove endotoxins and inflammatory cytokines versus the pioneering competitors who cannot accomplish both functions.

SIGY Set to Reach New Highs: Recent news prompted peers Aethlon Medical and Cytosorbents to enjoy major gains in recent weeks. Targeting multi-billion markets, SIGY's upcoming milestone events could serve as similar catalysts to move *its* stock 40% or more in the near term. .

SIGY TODAY, SIGY TOMORROW



Figure 1: Model Depiction of Sigyn Therapy

SIGY's flagship platform, Sigyn Therapy™, is a proprietary blood purification technology designed to overcome the limitations of previous drug and device candidates to treat acute inflammatory conditions, notably those preceded by Cytokine Storm Syndrome. The applications and potential indications represent unmet needs and, in many cases, there is no approved drug therapy. Given that the FDA established inflammatory cytokine reduction as a clinical endpoint to ameliorate cytokine storms that are induced by viral infections, we believe that SIGY's therapy could be cleared to treat sepsis, acute COVID-19 and other conditions---all representing vast, multi-billion-dollar markets.

In addition, since it appears that SIGY can treat high mortality inflammatory disorders induced by both viral and bacterial pathogens, SIGY may also be positioned to receive future clearance for use of its therapy for targeted indications including liver failure, such as hepatic encephalopathy and other conditions, making Sigyn Therapy™ the go-to therapy to treat acute, life-threatening inflammatory conditions.

The Big Picture

In the near term, leveraging multiple in vitro study results and future in vitro and animal model data, the Company is poised to file an Investigational Device Exemption (IDE) with the FDA later this year. In our view, this milestone is the trigger for substantial share price gains.

Meanwhile, there are two underlying themes related to SIGY that we believe could take the Company to leadership status among its peers and other medical device manufacturers. First, as evidenced by recent moves in the share prices of SIGY's peers, blood purification therapies are now demonstrating the unique capability to deliver life-saving mechanisms that are beyond the reach of post-infection drugs--especially during global health pandemics such as COVID-19. Moreover, much like we saw the difficulty in treating late stage COVID-19 patients suffering from CSS, the use of a blood purification therapy in late-stage patients suffering from conditions precipitated by CSS could halt these conditions and extend lives during the next health pandemic.

This shift is a big positive for the narrow segment as a whole. However, while there are blood purification devices cleared by the FDA to treat some of the aforementioned conditions, we believe that they fall a little short, relative to the potential capabilities of SIGY.

The Sigyn Therapy™ under development is designed to treat life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome, such as sepsis, COVID-19, etc. Unlike its peers, it appears that SIGY can address the source of high mortality inflammation induced by both viral and bacterial pathogens. Plus, the device may be the only one able to remove endotoxins and inflammatory cytokines versus the pioneering

competitors who cannot accomplish both functions. The device also establishes a therapeutic strategy to target CytoVesicles that transport inflammatory cargos throughout the circulatory system.

Separately, we should note that the Founder of SIGY peer Aethlon Medical oversaw the development of the Aethlon Hemopurifier. In our view, the convergence of his experience, along with that of co-founder Craig Roberts and his device, may have led to the development of a device to treat the full spectrum of inflammatory factors. Moreover, leveraging their collective experiences, the device is likely a superior offering with fewer components, and improved throughput.

Looking ahead, as the reach of the Company's offering grows, so too should the attention of the medical community, with the potentially broad use of its blood purification device as a standard-bearer in treating life-threatening conditions, whether it be induced by viral or bacterial pathogens. As noted earlier, we believe that SIGY could eventually be the first company to advance a medical device to treat Cytokine Storm Syndrome as its own categorical indication, as per the FDA. Clearly, such an event would catch the attention of prospective acquirers, thereby driving value toward levels unmatched by its peers.

Our six-twelve-month price target for SIGY remains \$9.00. This target reflects the value of prospective milestone achievements as the Company transitions from a development stage company to a clinical stage firm. It is affirmed by using a discounted potential value of revenue generated as an FDA-approved treatment for sepsis alone. In the near term, much like the rest of the space, we believe that major gains lie ahead for SIGY in the near term, with the shares potentially jumping by 40% based on future milestone achievements.



SENIOR ANALYST: ROBERT GOLDMAN

Rob Goldman founded Goldman Small Cap Research in 2009 and has over 25 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and *The Blue and White Fund*.

ANALYST CERTIFICATION

I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

DISCLAIMER

This *Opportunity Research* report was prepared for informational purposes only.

Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: *Goldman Select Research* and *Goldman Opportunity Research*. The *Select* format reflects the Firm's internally generated stock ideas along with economic and stock market outlooks. *Opportunity Research* reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro-cap research ideas that typically carry greater risks than those stocks covered in the *Select Research* category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the *Opportunity Research* format typically have a higher risk profile and may offer greater upside. *Goldman Small Cap Research* was compensated by the Company in the amount of \$7500 for research report and research update production and distribution. All information contained in this report was provided by the Company via filings, press releases or its website, or through our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. *Goldman Small Cap Research* did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. *Goldman Small Cap Research* relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such

information and the opinions expressed are subject to change without notice. A *Goldman Small Cap Research* report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither *Goldman Small Cap Research*, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED "AS IS" WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, *TWO TRIANGLE CONSULTING GROUP, LLC* WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, *TWO TRIANGLE CONSULTING GROUP, LLC* WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com